These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 25141899)

  • 21. Maximizing the clinical outcome with mTOR inhibitors in the renal transplant recipient: defining the role of calcineurin inhibitors.
    Nashan B
    Transpl Int; 2004 Jul; 17(6):279-85. PubMed ID: 15221123
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Association of a change in immunosuppressive regimen with hemodynamic and inflammatory markers of cardiovascular disease after kidney transplantation.
    Yong K; Nguyen HD; Hii L; Chan DT; Boudville N; Messineo A; Lim EM; Dogra GK; Lim WH
    Am J Hypertens; 2013 Jul; 26(7):843-9. PubMed ID: 23443728
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The pharmacogenetics of calcineurin inhibitors: one step closer toward individualized immunosuppression?
    Hesselink DA; van Gelder T; van Schaik RH
    Pharmacogenomics; 2005 Jun; 6(4):323-37. PubMed ID: 16004552
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The impact of calcineurin inhibitors on graft survival.
    Rush D
    Transplant Rev (Orlando); 2013 Jul; 27(3):93-5. PubMed ID: 23743217
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Calcineurin inhibitors and immunosuppression - a tale of two isoforms.
    Williams CR; Gooch JL
    Expert Rev Mol Med; 2012 Jul; 14():e14. PubMed ID: 22805659
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A comparative study on renal biopsy before and after long-term calcineurin inhibitors therapy: an insight for pathogenesis of its toxicity.
    Singh L; Singh G; Sharma A; Sinha A; Bagga A; Dinda AK
    Hum Pathol; 2015 Jan; 46(1):34-9. PubMed ID: 25449629
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Adverse Effects of Immunosuppression: Nephrotoxicity, Hypertension, and Metabolic Disease.
    Hoosain J; Hamad E
    Handb Exp Pharmacol; 2022; 272():337-348. PubMed ID: 34697665
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The pharmacogenetics of calcineurin inhibitor-related nephrotoxicity.
    Hesselink DA; Bouamar R; van Gelder T
    Ther Drug Monit; 2010 Aug; 32(4):387-93. PubMed ID: 20571464
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The pathophysiology of endothelin in complications after solid organ transplantation: a potential novel therapeutic role for endothelin receptor antagonists.
    Raina A; Horn ET; Benza RL
    Transplantation; 2012 Nov; 94(9):885-93. PubMed ID: 23037008
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacogenetics of calcineurin inhibitors in Brazilian renal transplant patients.
    Santoro A; Felipe CR; Tedesco-Silva H; Medina-Pestana JO; Struchiner CJ; Ojopi EB; Suarez-Kurtz G
    Pharmacogenomics; 2011 Sep; 12(9):1293-303. PubMed ID: 21806386
    [TBL] [Abstract][Full Text] [Related]  

  • 31. An up-date review on individualized dosage adjustment of calcineurin inhibitors in organ transplant patients.
    Masuda S; Inui K
    Pharmacol Ther; 2006 Oct; 112(1):184-98. PubMed ID: 16759707
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacogenomics of diuretic drugs: data on rare monogenic disorders and on polymorphisms and requirements for further research.
    Vormfelde SV; Burckhardt G; Zirk A; Wojnowski L; Brockmöller J
    Pharmacogenomics; 2003 Nov; 4(6):701-34. PubMed ID: 14596636
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Review of clinical trials on minimization and interruption of calcineurin inhibitors (CNIs) and protocols without CNIs in the transplantation of different organs (kidney, heart, and liver)].
    Albano L
    Nephrol Ther; 2009 Dec; 5 Suppl 6():S371-8. PubMed ID: 20129448
    [TBL] [Abstract][Full Text] [Related]  

  • 34. CNI induced Th17/Treg imbalance and susceptibility to renal dysfunction in renal transplantation.
    Li Y; Shi Y; Huang Z; Bai Y; Niu Q; Cai B; Wang L; Feng W
    Int Immunopharmacol; 2011 Dec; 11(12):2033-8. PubMed ID: 21911083
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Biotransformation enzymes and drug transporters pharmacogenetics in relation to immunosuppressive drugs: impact on pharmacokinetics and clinical outcome.
    Mourad M; Wallemacq P; De Meyer M; Malaise J; De Pauw L; Eddour DC; Goffin E; Lerut J; Haufroid V
    Transplantation; 2008 Apr; 85(7 Suppl):S19-24. PubMed ID: 18401258
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Calcineurin inhibitor-free immunosuppression in kidney transplantation.
    Guerra G; Srinivas TR; Meier-Kriesche HU
    Transpl Int; 2007 Oct; 20(10):813-27. PubMed ID: 17645419
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Conversion from a calcineurin inhibitor to everolimus therapy in maintenance liver transplant recipients: a prospective, randomized, multicenter trial.
    De Simone P; Metselaar HJ; Fischer L; Dumortier J; Boudjema K; Hardwigsen J; Rostaing L; De Carlis L; Saliba F; Nevens F
    Liver Transpl; 2009 Oct; 15(10):1262-9. PubMed ID: 19790150
    [TBL] [Abstract][Full Text] [Related]  

  • 38. CYP2C8*3 polymorphism and donor age are associated with allograft dysfunction in kidney transplant recipients treated with calcineurin inhibitors.
    Gervasini G; Garcia M; Macias RM; Benitez J; Caravaca F; Cubero JJ
    J Clin Pharmacol; 2013 Apr; 53(4):427-34. PubMed ID: 23426640
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Calcineurin inhibitor conversion to rapamycin can improve graft function in living donor kidney transplantation with older donors.
    Chen GD; Liu XC; Shi L; Qiu J; Wang CX; Fei JG; Li J; Huang G; Chen LZ
    Transplant Proc; 2013 May; 45(4):1648-50. PubMed ID: 23726640
    [TBL] [Abstract][Full Text] [Related]  

  • 40. YB-1 increases glomerular, but decreases interstitial fibrosis in CNI-induced nephropathy.
    Gibbert L; Hermert D; Wang J; M Breitkopf D; Alidousty C; Neusser M; Cohen CD; Gröne E; Macheleidt I; Rauen T; Braun GS; Floege J; Ostendorf T; Raffetseder U
    Clin Immunol; 2018 Sep; 194():67-74. PubMed ID: 30018024
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.